Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2012 Jan 12;551:357-66. doi: 10.1021/jm201231w.
Show Gene links
Show Anatomy links
(1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.
Pan Y
,
Gerasimov MR
,
Kvist T
,
Wellendorph P
,
Madsen KK
,
Pera E
,
Lee H
,
Schousboe A
,
Chebib M
,
Bräuner-Osborne H
,
Craft CM
,
Brodie JD
,
Schiffer WK
,
Dewey SL
,
Miller SR
,
Silverman RB
.
???displayArticle.abstract???
Vigabatrin, a GABA aminotransferase (GABA-AT) inactivator, is used to treat infantile spasms and refractory complex partial seizures and is in clinical trials to treat addiction. We evaluated a novel GABA-AT inactivator (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115, compound 1) and observed that it does not exhibit other GABAergic or off-target activities and is rapidly and completely orally absorbed and eliminated. By use of in vivo microdialysis techniques in freely moving rats and microPET imaging techniques, 1 produced similar inhibition of cocaine-induced increases in extracellular dopamine and in synaptic dopamine in the nucleus accumbens at (1)/(300) to (1)/(600) the dose of vigabatrin. It also blocks expression of cocaine-induced conditioned place preference at a dose (1)/(300) that of vigabatrin. Electroretinographic (ERG) responses in rats treated with 1, at doses 20-40 times higher than those needed to treat addiction in rats, exhibited reductions in ERG responses, which were less than the reductions observed in rats treated with vigabatrin at the same dose needed to treat addiction in rats. In conclusion, 1 can be administered at significantly lower doses than vigabatrin, which suggests a potential new treatment for addiction with a significantly reduced risk of visual field defects.
???displayArticle.pubmedLink???
22128851
???displayArticle.pmcLink???PMC3257419 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Ashby,
Implication of the GABA(B) receptor in gamma vinyl-GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine.
1999, Pubmed
Ashby,
Implication of the GABA(B) receptor in gamma vinyl-GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine.
1999,
Pubmed
Ashby,
Systemic administration of 1R,4S-4-amino-cyclopent-2-ene-carboxylic acid, a reversible inhibitor of GABA transaminase, blocks expression of conditioned place preference to cocaine and nicotine in rats.
2002,
Pubmed
Bolvig,
Action of bicyclic isoxazole GABA analogues on GABA transporters and its relation to anticonvulsant activity.
1999,
Pubmed
Brodie,
Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction.
2005,
Pubmed
Brodie,
Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA.
2003,
Pubmed
Brodie,
Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees.
2009,
Pubmed
Chebib,
The effects of cyclopentane and cyclopentene analogues of GABA at recombinant GABA(C) receptors.
2001,
Pubmed
,
Xenbase
Christiansen,
Cloning and characterization of a functional human gamma-aminobutyric acid (GABA) transporter, human GAT-2.
2007,
Pubmed
Dewey,
A novel strategy for the treatment of cocaine addiction.
1998,
Pubmed
Dewey,
A pharmacologic strategy for the treatment of nicotine addiction.
1999,
Pubmed
Duboc,
Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats.
2004,
Pubmed
Foletti,
Reduction of plasma alanine aminotransferase during vigabatrin treatment.
1995,
Pubmed
Gerasimov,
Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine.
1999,
Pubmed
Gibson,
Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor.
1990,
Pubmed
Harding,
Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss.
2000,
Pubmed
Hill,
3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain.
1981,
Pubmed
Høg,
Structure-activity relationships of selective GABA uptake inhibitors.
2006,
Pubmed
Izumi,
Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA.
2004,
Pubmed
Jammoul,
Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity.
2009,
Pubmed
Johnston,
Neurochemicals for the investigation of GABA(C) receptors.
2010,
Pubmed
Karila,
New treatments for cocaine dependence: a focused review.
2008,
Pubmed
Kvist,
The four human gamma-aminobutyric acid (GABA) transporters: pharmacological characterization and validation of a highly efficient screening assay.
2009,
Pubmed
Lippert,
4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain.
1977,
Pubmed
Liu,
Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected].
1993,
Pubmed
,
Xenbase
Madsen,
Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs.
2009,
Pubmed
McCoy,
Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?
2011,
Pubmed
Meldrum,
Molecular targets for antiepileptic drug development.
2007,
Pubmed
Molina,
Co-administration of gamma-vinyl GABA and cocaine: preclinical assessment of safety.
1999,
Pubmed
Morgan,
Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine.
1998,
Pubmed
Pan,
Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent gamma-aminobutyric acid aminotransferase inhibitor.
2003,
Pubmed
Pellock,
Registry initiated to characterize vision loss associated with vigabatrin therapy.
2011,
Pubmed
Peng,
Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism.
2008,
Pubmed
Ponjavic,
Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
2001,
Pubmed
Ransom,
Cooperative modulation of [3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines.
1988,
Pubmed
Roberts,
Ocular phototoxicity.
2001,
Pubmed
Sherif,
Basic aspects of GABA-transaminase in neuropsychiatric disorders.
1995,
Pubmed
Sills,
Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study.
1999,
Pubmed
Silverman,
Mechanism-based enzyme inactivators.
1995,
Pubmed
Stromberg,
The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat.
2001,
Pubmed
Valdizán,
Effects of single and multiple increasing doses of vigabatrin on brain GABA metabolism and correlation with vigabatrin plasma concentration.
1992,
Pubmed
White,
Correlation between anticonvulsant activity and inhibitory action on glial gamma-aminobutyric acid uptake of the highly selective mouse gamma-aminobutyric acid transporter 1 inhibitor 3-hydroxy-4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its N-alkylated analogs.
2002,
Pubmed
Wild,
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study.
2009,
Pubmed
Willmore,
Vigabatrin: 2008 update.
2009,
Pubmed
